R
Richard E. Cutler
Researcher at Onyx Pharmaceuticals
Publications - 34
Citations - 1127
Richard E. Cutler is an academic researcher from Onyx Pharmaceuticals. The author has contributed to research in topics: Neratinib & Breast cancer. The author has an hindex of 13, co-authored 33 publications receiving 802 citations. Previous affiliations of Richard E. Cutler include University of Texas Health Science Center at Houston.
Papers
More filters
Journal ArticleDOI
HER kinase inhibition in patients with HER2- and HER3-mutant cancers.
David M. Hyman,Sarina Anne Piha-Paul,Helen Won,Jordi Rodon,Cristina Saura,Geoffrey I. Shapiro,Dejan Juric,David I. Quinn,Victor Moreno,Bernard Doger,Ingrid A. Mayer,Valentina Boni,Emiliano Calvo,Sherene Loi,Albert C. Lockhart,Joseph P. Erinjeri,Maurizio Scaltriti,Gary A. Ulaner,Juber Patel,Jiabin Tang,Hannah Beer,S. Duygu Selcuklu,Aphrothiti J. Hanrahan,Nancy Bouvier,Myra Melcer,Rajmohan Murali,Alison M. Schram,Lillian M. Smyth,Komal Jhaveri,Bob T. Li,Alexander Drilon,James J. Harding,Gopa Iyer,Barry S. Taylor,Michael F. Berger,Richard E. Cutler,Feng Xu,Anna Butturini,Lisa D. Eli,Grace Mann,Cynthia Farrell,Alshad S. Lalani,Richard Bryce,Carlos L. Arteaga,Funda Meric-Bernstam,José Baselga,David B. Solit +46 more
TL;DR: This study demonstrates how a molecularly driven clinical trial can be used to refine the biological understanding of both characterized and new genomic alterations with potential broad applicability for advancing the paradigm of genome-driven oncology.
Journal ArticleDOI
An Acquired HER2T798I Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant-Driven Breast Cancer.
Ariella B. Hanker,Monica Red Brewer,Jonathan H. Sheehan,James P. Koch,Gregory Sliwoski,Rebecca J. Nagy,Richard B. Lanman,Michael F. Berger,David M. Hyman,David B. Solit,Jie He,Vincent A. Miller,Richard E. Cutler,Alshad S. Lalani,Darren Cross,Christine M. Lovly,Jens Meiler,Carlos L. Arteaga +17 more
TL;DR: It is speculated that HER2T798I may arise as a secondary mutation following response to effective HER2 tyrosine kinase inhibitors (TKI) in other cancers with HER2-activating mutations and this resistance may be overcome by other irreversible HER2 TKIs, such as afatinib.
Journal ArticleDOI
A phase I/II study of carfilzomib 2–10-min infusion in patients with advanced solid tumors
Kyriakos P. Papadopoulos,Howard A. Burris,Michael S. Gordon,Peter P. Lee,Peter P. Lee,Edward A. Sausville,Peter Rosen,Peter Rosen,Amita Patnaik,Richard E. Cutler,Zhengping Wang,Susan Lee,Suzanne F. Jones,J. R. Infante +13 more
TL;DR: Carfilzomib 20/36 mg/m2 was well tolerated when administered twice weekly by 2–10-min IV infusion and inhibited the proteasome in blood but demonstrated limited antitumor activity in patients with advanced solid tumors.
Journal ArticleDOI
Combined blockade of activating ERBB2 mutations and ER results in synthetic lethality of ER+/HER2 mutant breast cancer
Sarah Croessmann,Luigi Formisano,Lisa N. Kinch,Paula I. Gonzalez-Ericsson,Dhivya R. Sudhan,Rebecca J. Nagy,Aju Mathew,Eric H. Bernicker,Massimo Cristofanilli,Jie He,Richard E. Cutler,Alshad S. Lalani,Vincent A. Miller,Richard B. Lanman,Nick V. Grishin,Carlos L. Arteaga +15 more
TL;DR: ERBB2 mutations hyperactivate the HER3/PI3K/AKT/mTOR axis, leading to antiestrogen resistance in ER+ breast cancer and dual blockade of the HER2 and ER pathways is required for the treatment of ER+/HER2 mutant breast cancers.
Journal ArticleDOI
HDAC inhibitors enhance neratinib activity and when combined enhance the actions of an anti-PD-1 immunomodulatory antibody in vivo
Laurence Booth,Jane L. Roberts,Andrew Poklepovic,Francesca Avogadri-Connors,Richard E. Cutler,Alshad S. Lalani,Paul Dent +6 more
TL;DR: The premises that neratinib lethality can be enhanced by HDAC inhibitors, that Neratinib may be a useful therapeutic tool in afatinib resistant NSCLC, and that [neratinib + HDAC inhibitor] exposure facilitates anti-tumor immune responses are supported.